A prospective PMS study to validate the sensitivity for change of the D- scale in advanced stages of dementia using the NMDA-antagonist memantine

Pharmacopsychiatry

Volumn 33, Issue 3, 2000, Pages 103-108

  Rüther, Eckart ^a   Glaser, A ^b   Bleich, S ^a   Degner, D ^a   Wiltfang, J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Georg August Universität ^*

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID;

ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITION; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MOTOR PERFORMANCE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; VALIDATION PROCESS;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; COGNITION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MOTOR ACTIVITY; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0347278758     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-341     Document Type: Article

References (22)

1. 1 Arnold K, Lehfeld H, Mösler Th, Erzigkeit H: Scale properties of the D-Scale in severe dementia.6th Int. Conf. Alzheimer's Disease Amsterdam. 1998
2. 2 Bergener M, Reisberg B, (Eds.): Diagnosis and treatment of senile dementia. Springer Verlag BerlinHeidelberg. 1989
3. 3 CIPS, (ed): Internationale Skalen für Psychiatrie (4. Auflage). Beltz TestGöttingen. 1996
4. 4 Committee for Proprietry Medicinal Products (CPMP): Note for Guidance on medicinal products in the treatment of Alzheimer's disease. CPMP//EWP/533/95London. 1997
5. 5 Ditzler K: Efficacy and tolerability of memantine in patients with dementia syndrome. Drug Res 1991; 41: 773-780
6. 6 Fern L: Behavioral Activities in demented geriatric patients. Geront. Clin. 1974; 16: 185-194
7. 7 Galasko D, Bennett M, Sano M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis. Assoc. Disorders 1997; 11,Suppl. 2: 33-39
8. 8 Görtelmeyer R, Erbler H: Memantine in the treatment of mild to moderate dementia syndrome. Drug Res. 1992; 42: 904-913
9. 9 Gottfries CG, Brain G, Steen G: A new rating scale for dementia syndromes. Gerontology 1982; 28, Suppl. 2: 20-31
10. 10 Greenamyre JT, Young AB: Excitatory amino acids and Alzheimer's disease. Neurobiol. Aging 1989; 10: 593-602
11. 11 Guy W: Early clinical drug evaluation (ECDEU). Assessment Manual for Psychopharmacology 1976
12. 12 Kam P, Mol F, Wimmers MFMG: Beurteilungsskalen für geriatrische Patienten (BGP) (CIPS) Internationale Skalen für Psychiatrie, 4. Auflage. Beltz TestGöttingen. 1996
13. 13 Meer B, Baker JA: The Stockton geriatric rating scale. J. Gerontol. 1966; 21: 392-403
14. 14 Misztal M, Frankiewicz T, Parsons CG, Danysz W: Learning deficits induced by chronic intraventricular infusion of quinolinic acid -protection by MK-801 and memantine. European Journal of Pharmacology 1996; 296: 1-8
15. 15 Pantev M, Ritter R, Görtelmeyer R: Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Zeitschrift für Geronto-psychologie und -psychiatrie 1993; 6: 103-117
16. 16 Parsons CG, Danysz W, Quack G: Memantine is a clinically well tolerated NMDA Receptor Antagonist - a review of preclinical data. Neuropharmacology 1999; 38: 735-767
17. 17 Reisberg B, Ferris SH, de Leon MY, Crook T: The global deterioration scale (GDS): an instrument for the assessment of primary degenerative dementia (PDD). Am. J. Psychiat. 1992; 139: 1136-1139
18. 18 Rüther E, Glaser A: The NMDA-antagonist memantine in severe dementia: Results of a prospective post-marketing surveillance study. 6th Int. Conf. Alzheimer's DiseaseAmsterdam. 1998
19. 19 Seif el Nasr M, Peruche B, Roßberg C, Mennel HD, Krieglstein J: Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J. Pharmacol. 1990; 185: 19-24
20. 20 Wimo A, Ljunggren G, Winblad B: Costs of dementia care: a review. Int. J. Geriat. Psychiatry 1997; 12: 841-856
21. 21 Winblad B, Poritis N: Memantine in severe dementia. Int. J. Geriat. Psychiatry 1999; 14: 135-146
22. 22 Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W: Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 1997; 36: 961-971